IDIAPJGol promotes E-SPERANZA COVID: an independent clinical trial on persistent Covid-19
The E-SPERANZA COVID is an independent clinical trial that will evaluate the effectiveness of Montelukast, an already marketed drug used in people with asthma. The trial, an independent study, has been submitted to several calls for funding, and also opts for external funding. The clinical trial is directed by the family doctor of the Center d'Atenció Primària El Pla de Sant Feliu de Llobregat of the Direcció d'Atenció Primària Costa Ponent de l'Institut Català de la Salut, and researcher at the IDIAPJGol Francisco Mera Cordero.